Date published: 2026-4-23

1-800-457-3801

SCBT Portrait Logo
Seach Input

VILIP-2 Inhibitors

VILIP-2 inhibitors are a category of chemical agents designed to selectively bind to and inhibit the activity of Visinin-like protein 2 (VILIP-2). VILIP-2 belongs to the neuronal calcium sensor (NCS) family of proteins, which play a critical role in intracellular calcium signaling pathways. These proteins are capable of translating calcium ion fluxes into changes in cellular function, hence their importance in a variety of biological processes. VILIP-2 inhibitors interact with this protein to modulate its normal activity. The specific interaction between VILIP-2 and its inhibitors often involves the obstruction of the protein's calcium-binding sites or the interference with its conformational changes, which are necessary for its function. The development of these inhibitors typically requires a thorough understanding of VILIP-2's structure, including its active and allosteric sites, to ensure high specificity and affinity of the inhibitors towards the target protein. Sophisticated techniques such as computational modeling and biophysical assays are employed in the design process to identify and optimize potential inhibitory molecules that can effectively interact with VILIP-2.

The discovery and enhancement of VILIP-2 inhibitors involve a meticulous chemical synthesis process that often begins with the identification of core molecular scaffolds capable of engaging VILIP-2. These scaffolds are then elaborated upon through the addition of various functional groups, aiming to enhance molecular interactions with the protein's binding sites. The process is highly iterative, with cycles of design, synthesis, and testing to refine the molecular structure for improved potency and selectivity. The chemical structures of VILIP-2 inhibitors can vary significantly, with the incorporation of diverse chemical moieties to exploit the unique environment of VILIP-2's binding pockets.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

BAPTA/AM

126150-97-8sc-202488
sc-202488A
25 mg
100 mg
$138.00
$458.00
61
(2)

Intracellular calcium chelator that can affect calcium-dependent signaling pathways and thereby indirectly modulate VILIP-2-associated functions.

Nifedipine

21829-25-4sc-3589
sc-3589A
1 g
5 g
$59.00
$173.00
15
(1)

L-type calcium channel blocker which can influence intracellular calcium dynamics and thus indirectly influence VILIP-2's activation.

Verapamil

52-53-9sc-507373
1 g
$374.00
(0)

Another L-type calcium channel blocker that can modulate calcium signaling pathways potentially related to VILIP-2.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$136.00
$446.00
114
(2)

SERCA pump inhibitor that increases intracellular calcium levels, influencing calcium-dependent proteins including VILIP-2.

2-APB

524-95-8sc-201487
sc-201487A
20 mg
100 mg
$28.00
$53.00
37
(1)

Inhibits IP3 receptors and TRP channels, modulating calcium signaling and potentially affecting pathways where VILIP-2 is involved.

Dantrolene

7261-97-4sc-500165
25 mg
$350.00
7
(0)

RyR calcium release channel inhibitor, affecting intracellular calcium dynamics which can in turn influence VILIP-2's role.

TMB-8 • HCl

53464-72-5sc-3522
sc-3522A
10 mg
50 mg
$43.00
$129.00
10
(1)

Inhibits calcium release from intracellular stores, potentially modulating calcium-dependent processes where VILIP-2 functions.

W-7

61714-27-0sc-201501
sc-201501A
sc-201501B
50 mg
100 mg
1 g
$166.00
$306.00
$1675.00
18
(1)

Calmodulin antagonist that can indirectly impact VILIP-2 by modulating calcium-dependent signaling pathways.

Nimodipine

66085-59-4sc-201464
sc-201464A
100 mg
1 g
$61.00
$307.00
2
(1)

L-type calcium channel blocker that influences intracellular calcium levels, potentially affecting VILIP-2-associated signaling.

SK&F 96365

130495-35-1sc-201475
sc-201475B
sc-201475A
sc-201475C
5 mg
10 mg
25 mg
50 mg
$103.00
$158.00
$397.00
$656.00
2
(1)

Inhibitor of receptor-mediated calcium entry, which can indirectly modulate VILIP-2's activation.